BioSpace News Archive

Abstract vector storm clouds with thunder hand drawn chaotic tangle of doodles.Sign bad weather,impending rain and storm,thunder rolls.Symbol stress,depression,psychosis,mental crisis personality,headache after suffering coronavirus.

Career Advice

Dealing with a toxic co-worker can be exhausting, and it can make your workplace more stressful. There are a few ways to make it easier, including developing healthy coping mechanisms and even talking it out with your colleague.

September 25, 2024

·

5 min read

·

Alina Zahid

Policy

Novo’s Ozempic Seen as Shoo-In for Next Round of Medicare Price Negotiations

Novo Nordisk’s blockbuster type 2 diabetes medication is a sure bet for the list of the next 15 drugs whose Medicare prices will be negotiated in 2025 and go into effect in 2027, according to analysts and academics.

September 25, 2024

·

3 min read

·

Greg Slabodkin

Pictured: Amgen's office in Tampa, Florida

Phase III

Amgen Scores Late-Stage Wins in Eczema and Myasthenia Gravis, But Analysts See Mixed Results

Jefferies analyst Michael Yee in a note to investors called rocatinlimab’s atopic dermatitis data “modest,” noting that the OX40 receptor blocker “came in at the lower end of efficacy and expectations,” but found Uplizna’s performance in generalized myasthenia gravis “better than expected.”

September 25, 2024

·

2 min read

·

Tristan Manalac

Regulatory

FDA Considers Narrowing Label of PD-1 Drugs in Stomach Cancer Ahead of Adcomm Meeting

If approved, the potential restrictions would impact Merck’s Keytruda and Bristol Myers Squibb’s Opdivo, which are marketed for the first-line treatment of several types of stomach cancer regardless of PD-L1 expression.

September 25, 2024

·

2 min read

·

Tristan Manalac

Pictured: Merck building and sign in Silicon Valley

Cancer

Merck’s Keytruda Combo Fails in Phase III Colorectal Cancer Study

Merck follows in the footsteps of Bristol Myers Squibb, which in December 2023 also failed to secure a late-stage victory for its combo regimen of a PD-1 blocker and an anti-LAG-3 antibody.

September 25, 2024

·

2 min read

·

Tristan Manalac

Podcast

Novo Grilled by Senate, PhRMA’s IRA Win and BMS’ KarXT Awaits Approval

New revelations from the showdown between Novo Nordisk’s CEO and Bernie Sanders’ Senate health committee Tuesday; PhRMA’s legal victory in IRA case; the federal interest rate cut and anticipated approval for schizophrenia.

September 25, 2024

·

1 min read

·

Heather McKenzie

IRA

Cancer and Diabetes Drugs Expected to Dominate 2025 Medicare Negotiations Under IRA

Many Big Pharma companies including Pfizer, Merck and BMS make the drugs that some researchers expect to be selected by CMS for next year’s Medicare price negotiations alongside analysts’ top pick, Novo Nordisk’s Ozempic.

September 25, 2024

·

2 min read

·

Greg Slabodkin

External view of the U.S. Capitol building

Business

Novo CEO Reluctantly Agrees to Meet With PBMs on Ozempic, Wegovy Prices

In a Tuesday Senate hearing on Novo Nordisk’s drug pricing, CEO Lars Fruergaard Jørgensen said he would be willing to sit down with the three largest pharmacy benefit managers who committed that they would expand coverage of Ozempic and Wegovy if Novo lowers its list prices for the blockbuster drugs.

September 25, 2024

·

3 min read

·

Greg Slabodkin

Deals

Lilly and Novo Spend Billions to Expand Obesity Pipelines Beyond GLP-1s

Novo Nordisk and Eli Lilly are expected to rule the obesity market for a few more years without much challenge. To ensure they stay there as competition enters, the companies are spending billions in licensing and M&A deals.

September 25, 2024

·

10 min read

·

Annalee Armstrong

FDA signage at its headquarters in Maryland

Approvals

IntraBio Wins FDA Nod for Ultra-Rare Neurodegenerative Disease on Heels of Competitor’s Approval

IntraBio’s Aqneursa is the second drug within a week approved by the regulator for treating Niemann-Pick disease type C, just days behind Zevra Therapeutics’ Miplyffa.

September 25, 2024

·

2 min read

·

Tristan Manalac